WEIGHT-CHANGE GUIDED TAILORED DIURETIC THERAPY TO DECOMPENSATED CONGESTIVE HEART FAILURE: A RANDOMIZED TRIAL  by Cardoso, Juliano Novaes et al.
E223
JACC April 5, 2011
Volume 57, Issue 17
  CARDIAC FUNCTION AND HEART FAILURE 
WEIGHT-CHANGE GUIDED TAILORED DIURETIC THERAPY TO DECOMPENSATED CONGESTIVE HEART 
FAILURE: A RANDOMIZED TRIAL
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: Myocardial Function/Heart Failure - - Clinical Pharmacological Treatment
Abstract Category: 21. Myocardial Function/Heart Failure—Clinical Pharmacological Treatment
Session-Poster Board Number: 1017-44
Authors: Juliano Novaes Cardoso, Marcelo Eidi Ochiai, Paulo Cesar Morgado, Robinson Tadeu Munhoz, Múcio Tavares Oliveira, Milena Curuatti, 
Cristina Martins Reis, Kelly Regina, Antonio Pereira Barretto, Instituto do Coração de São Paulo-HACotoxó-HCFMUSP, São Paulo, Brazil
Background:  Diuretic is a fundamental part of treatment of decompensated congestive heart failure but are prescribed in empirical way and 
worsening renal function is frequent.
Methods:  evaluate a tailored diuretic therapy based on daily weight-change. In a randomized clinical trial, patients hospitalized by 
decompensated heart failure, ejection fraction < 0.45, were assigned to tailored (group T) or standard (group C) diuretic therapy. Expected weight 
change was defined -1.4%/day. Tailored therapy was initial dose (furosemide 120mg/d iv, plus hydroclortiazide 50 mg/d po) corrected daily by 
observed/expected (O/E) weight change ratio. If O/E ratio was > 2.0, furosemide was reduced by 33.3%. If O/E ratio was < 0.5, furosemide was 
increased by 33.3%. O/E ratio between 0.5 and 1.99, furosemide dose was maintained. Endpoints were worsening renal function (WRF - increase > 
0.3 mg/dL) and time to compensation (free of congestion). P < 0.05 was significant.
Results:  72 patients were randomized, with age 58.1 years (11.8), ejection fraction was 23.1 % (6.59), 27.8% with ischemic myocardiopathy. The 
baseline creatinine was 1.33 (0.38) mg/dL. WRF was similar (Group T: 26.5% vs. Group C: 26.3%, P=0.988), the weight change at day 5 was greater 
in group T: -8.15% (4.9) vs. -4.35% (4.14) P=0.001. The time for free from signs and symptoms of congestion was smaller in group T (Figure 1).
Conclusion: Tailored diuretic therapy was associated with greater weight loss and congestion improvement. WRF was similar in both groups. 
